MedRx Co., Ltd (TYO:4586)
Japan · Delayed Price · Currency is JPY 67.00
+1.00 (1.52%)
Aug 27, 2026, 3:30 PM JST
MedRx Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,143 | 1,754 | 1,977 | 1,720 | 994 | 1,703 |
Cash & Short-Term Investments | 1,143 | 1,754 | 1,977 | 1,720 | 994 | 1,703 |
Cash Growth | -31.43% | -11.28% | 14.94% | 73.04% | -41.63% | -6.02% |
Other Receivables | 15 | 12 | 44 | 33 | 15 | 23 |
Receivables | 15 | 12 | 44 | 33 | 15 | 23 |
Inventory | 39 | 16 | 10 | 10 | 8 | 11 |
Other Current Assets | 146 | 42 | 41 | 22 | 70 | 17 |
Total Current Assets | 1,343 | 1,824 | 2,072 | 1,785 | 1,087 | 1,754 |
Property, Plant & Equipment | 190 | 192 | 123 | 181 | 226 | 270 |
Long-Term Investments | 208 | 140 | 79 | 85 | 84 | 83 |
Other Long-Term Assets | 1 | 1 | 1 | 1 | 1 | 1 |
Total Assets | 1,742 | 2,157 | 2,275 | 2,052 | 1,398 | 2,108 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Current Income Taxes Payable | 93 | 75 | 103 | 98 | 156 | 124 |
Other Current Liabilities | 3 | 2 | 2 | 1 | 2 | 1 |
Total Current Liabilities | 96 | 77 | 105 | 99 | 158 | 125 |
Long-Term Deferred Tax Liabilities | 53 | 31 | - | 4 | 5 | 5 |
Other Long-Term Liabilities | 2 | 2 | 2 | 26 | 24 | 23 |
Total Liabilities | 151 | 110 | 107 | 129 | 187 | 153 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 73 | 450 | 580 | 847 | 227 | 7,803 |
Additional Paid-In Capital | 1,816 | 2,358 | 2,314 | 1,916 | 3,063 | 7,372 |
Retained Earnings | -484 | -898 | -787 | -915 | -2,150 | -13,279 |
Comprehensive Income & Other | 186 | 137 | 61 | 75 | 71 | 59 |
Shareholders' Equity | 1,591 | 2,047 | 2,168 | 1,923 | 1,211 | 1,955 |
Total Liabilities & Equity | 1,742 | 2,157 | 2,275 | 2,052 | 1,398 | 2,108 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 1,143 | 1,754 | 1,977 | 1,720 | 994 | 1,703 |
Net Cash Growth | -31.43% | -11.28% | 14.94% | 73.04% | -41.63% | -3.35% |
Net Cash Per Share | 19.40 | 32.64 | 45.48 | 49.46 | 39.19 | 79.74 |
Filing Date Shares Outstanding | 59.62 | 59.37 | 47.5 | 38.48 | 30.7 | 24.6 |
Total Common Shares Outstanding | 59.62 | 59.37 | 47.5 | 38.37 | 28.22 | 24.6 |
Working Capital | 1,247 | 1,747 | 1,967 | 1,686 | 929 | 1,629 |
Book Value Per Share | 26.68 | 34.48 | 45.65 | 50.12 | 42.91 | 79.49 |
Tangible Book Value | 1,591 | 2,047 | 2,168 | 1,923 | 1,211 | 1,955 |
Tangible Book Value Per Share | 26.68 | 34.48 | 45.65 | 50.12 | 42.91 | 79.49 |
Order Backlog | - | - | - | - | 2 | - |